Comprehensive analysis of the main effects of Anamorelin

Anamorelin (Anamorelin) is an oral appetite-stimulating drug. Its main target is the growth hormone-releasing peptide (Ghrelin) receptor. It activates hypothalamic-related neural circuits by simulating Ghrelin, thereby enhancing appetite, increasing energy intake, and improving lean body mass loss. It is primarily used in patients with cancer wasting syndrome, especially those who do not respond well to traditional nutritional interventions and high-calorie diets. Clinical studies have shown that anamorelin can significantly increase lean body mass and improve weight management, while also helping to relieve fatigue and improve mobility, improving patients' quality of life. By activating Ghrelin receptors, anamorelin not only promotes appetite, but also enhances muscle protein synthesis and energy balance, allowing patients to maintain muscle mass and function under severe physical depletion.

In addition, anamorelin can improve the patient's mental state and exercise tolerance, increase participation in rehabilitation training, and enable patients to have more strength to carry out daily life and rehabilitation activities. Due to its oral administration method, treatment compliance is high and it facilitates long-term use in the home or outpatient setting. The efficacy of anamorelin varies between individuals and is greatly affected by basic body weight, cancer type, treatment stage and accompanying drugs. Therefore, body weight, lean body mass, blood sugar, liver function and cardiovascular indicators need to be regularly assessed during the treatment process, and the treatment plan should be adjusted based on clinical response to ensure the best efficacy and safety. At the same time, anamorelin is often used in conjunction with nutritional intervention, rehabilitation training and other symptomatic treatments to further enhance patients' physical fitness, muscle mass and overall quality of life.

Overall, anamorelin provides a new drug intervention strategy for cancer wasting syndrome, showing obvious advantages especially in patients who are refractory to traditional methods. It can not only improve body weight and muscle mass, but may also indirectly improve patients' immune function and recovery ability. It is an important drug choice for modern clinical management of cancer-wasting diseases.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/